Natures Sunshine Products Inc
A maker of nutritional supplements and personal care products, sold under the Nature's Sunshine Products and Synergy WorldWide brands through a network of independent consultants in regions from Asia to the Americas. It all started in 1972 when Gene Hughes, trying cayenne pepper for a digestive ailment, found it awful to swallow by the spoonful — so he and his wife Kristine hand-filled the powder into gelatin capsules at their kitchen table in Utah, an approach that helped launch the modern supplement industry. The company's name reflects its mission of sharing the healing power of nature.
Item 4 is hereby amended by adding the following paragraphs: On June 25, 2025, FPUSA, as selling stockholder, and the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with D.A. Davidson & Co. (the "Underwriter"), providing for the offer and sale of 2,854,607 shares of Common Stock (the "Shares"), being sold by FPUSA at a public offering price of $12.00 per share (the "Offering"), less the underwriting discounts and commissions of $0.54 per share, resulting in net proceeds to FPUSA of $11.46 per share. The Offering closed on June 27, 2025. The Offering was made pursuant to the Issuer's shelf registration statement (which includes a base prospectus) on Form S-3 (File No. 333-287882) that was filed with the SEC on June 9, 2025 and became effective on June 18, 2025. The base prospectus included in the registration statement, was amended and supplemented by the preliminary prospectus supplement filed with the SEC on June 25, 2025, and the final prospectus supplement filed with the SEC on June 27, 2025. Pursuant to the Underwriting Agreement, FPUSA has entered into a lock-up agreement (the "Lock-Up Agreement") pursuant to which FPUSA has agreed not to sell or transfer any securities of the Issuer held by it for a period of 90 days from June 27, 2025, subject to limited exceptions. In connection with the Offering, FPUSA entered into a share repurchase agreement (the "Share Repurchase Agreement") with the Issuer, pursuant to which the Issuer agreed that it may purchase up to $15.0 million of the shares of the Issuer's Common Stock that are subject to the Offering from the Underwriter at the public offering price as part of its previously announced share repurchase program. The descriptions of the Underwriting Agreement, Lock-up Agreement, and Share Repurchase Agreement contained in this Item 4 are not intended to be complete and are qualified in their entirety by reference to the Underwriting Agreement, Form of Lock-Up Agreement and Share Repurchase Agreement, each of which is filed as an exhibit hereto and incorporated by reference herein.
Item 4 is hereby amended by adding the following paragraphs: On June 25, 2025, FPUSA, as selling stockholder, and the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with D.A. Davidson & Co. (the "Underwriter"), providing for the offer and sale of 2,854,607 shares of Common Stock (the "Shares"), being sold by FPUSA at a public offering price of $12.00 per share (the "Offering"), less the underwriting discounts and commissions of $0.54 per share, resulting in net proceeds to FPUSA of $11.46 per share. The Offering closed on June 27, 2025. The Offering was made pursuant to the Issuer's shelf registration statement (which includes a base prospectus) on Form S-3 (File No. 333-287882) that was filed with the SEC on June 9, 2025 and became effective on June 18, 2025. The base prospectus included in the registration statement, was amended and supplemented by the preliminary prospectus supplement filed with the SEC on June 25, 2025, and the final prospectus supplement filed with the SEC on June 27, 2025. Pursuant to the Underwriting Agreement, FPUSA has entered into a lock-up agreement (the "Lock-Up Agreement") pursuant to which FPUSA has agreed not to sell or transfer any securities of the Issuer held by it for a period of 90 days from June 27, 2025, subject to limited exceptions. In connection with the Offering, FPUSA entered into a share repurchase agreement (the "Share Repurchase Agreement") with the Issuer, pursuant to which the Issuer agreed that it may purchase up to $15.0 million of the shares of the Issuer's Common Stock that are subject to the Offering from the Underwriter at the public offering price as part of its previously announced share repurchase program. The descriptions of the Underwriting Agreement, Lock-up Agreement, and Share Repurchase Agreement contained in this Item 4 are not intended to be complete and are qualified in their entirety by reference to the Underwriting Agreement, Form of Lock-Up Agreement and Share Repurchase Agreement, each of which is filed as an exhibit hereto and incorporated by reference herein.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| PRESCOTT GROUP CAPITAL MANAGEMENT, L.L.C. | 13G/APassive | 10.9% | 1.92M | Aug 10, 2026 |
| PRESCOTT GROUP AGGRESSIVE SMALL CAP LP | 13G/APassive | 10.9% | 1.92M | Aug 10, 2026 |
| PRESCOTT GROUP AGGRESSIVE SMALL CAP II LP | 13G/APassive | 10.9% | 1.92M | Aug 10, 2026 |
| PRESCOTT GROUP AGGRESSIVE SMALL CAP MASTER FUND GP | 13G/APassive | 10.9% | 1.92M | Aug 10, 2026 |
| FROHLICH PHIL | 13G/APassive | 10.9% | 1.92M | Aug 10, 2026 |
| BlackRock, Inc. | 13GPassive | 5.04% | 889.8K | Oct 17, 2025 |
| Dimensional Fund Advisors LP | 13GPassive | 5.2% | 913.8K | Oct 9, 2025 |
| Shanghai Fosun Pharmaceutical (Group) Co., Ltd. | 13D/AActivist | 0.35% | 64.2K | Jun 27, 2025 |
Item 4 is hereby amended by adding the following paragraphs: On June 25, 2025, FPUSA, as selling stockholder, and the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with D.A. Davidson & Co. (the "Underwriter"), providing for the offer and sale of 2,854,607 shares of Common Stock (the "Shares"), being sold by FPUSA at a public offering price of $12.00 per share (the "Offering"), less the underwriting discounts and commissions of $0.54 per share, resulting in net proceeds to FPUSA of $11.46 per share. The Offering closed on June 27, 2025. The Offering was made pursuant to the Issuer's shelf registration statement (which includes a base prospectus) on Form S-3 (File No. 333-287882) that was filed with the SEC on June 9, 2025 and became effective on June 18, 2025. The base prospectus included in the registration statement, was amended and supplemented by the preliminary prospectus supplement filed with the SEC on June 25, 2025, and the final prospectus supplement filed with the SEC on June 27, 2025. Pursuant to the Underwriting Agreement, FPUSA has entered into a lock-up agreement (the "Lock-Up Agreement") pursuant to which FPUSA has agreed not to sell or transfer any securities of the Issuer held by it for a period of 90 days from June 27, 2025, subject to limited exceptions. In connection with the Offering, FPUSA entered into a share repurchase agreement (the "Share Repurchase Agreement") with the Issuer, pursuant to which the Issuer agreed that it may purchase up to $15.0 million of the shares of the Issuer's Common Stock that are subject to the Offering from the Underwriter at the public offering price as part of its previously announced share repurchase program. The descriptions of the Underwriting Agreement, Lock-up Agreement, and Share Repurchase Agreement contained in this Item 4 are not intended to be complete and are qualified in their entirety by reference to the Underwriting Agreement, Form of Lock-Up Agreement and Share Repurchase Agreement, each of which is filed as an exhibit hereto and incorporated by reference herein. | ||||
| Fosun Pharma USA Inc. | 13D/AActivist | 0% | 0 | Jun 27, 2025 |
Item 4 is hereby amended by adding the following paragraphs: On June 25, 2025, FPUSA, as selling stockholder, and the Issuer entered into an underwriting agreement (the "Underwriting Agreement") with D.A. Davidson & Co. (the "Underwriter"), providing for the offer and sale of 2,854,607 shares of Common Stock (the "Shares"), being sold by FPUSA at a public offering price of $12.00 per share (the "Offering"), less the underwriting discounts and commissions of $0.54 per share, resulting in net proceeds to FPUSA of $11.46 per share. The Offering closed on June 27, 2025. The Offering was made pursuant to the Issuer's shelf registration statement (which includes a base prospectus) on Form S-3 (File No. 333-287882) that was filed with the SEC on June 9, 2025 and became effective on June 18, 2025. The base prospectus included in the registration statement, was amended and supplemented by the preliminary prospectus supplement filed with the SEC on June 25, 2025, and the final prospectus supplement filed with the SEC on June 27, 2025. Pursuant to the Underwriting Agreement, FPUSA has entered into a lock-up agreement (the "Lock-Up Agreement") pursuant to which FPUSA has agreed not to sell or transfer any securities of the Issuer held by it for a period of 90 days from June 27, 2025, subject to limited exceptions. In connection with the Offering, FPUSA entered into a share repurchase agreement (the "Share Repurchase Agreement") with the Issuer, pursuant to which the Issuer agreed that it may purchase up to $15.0 million of the shares of the Issuer's Common Stock that are subject to the Offering from the Underwriter at the public offering price as part of its previously announced share repurchase program. The descriptions of the Underwriting Agreement, Lock-up Agreement, and Share Repurchase Agreement contained in this Item 4 are not intended to be complete and are qualified in their entirety by reference to the Underwriting Agreement, Form of Lock-Up Agreement and Share Repurchase Agreement, each of which is filed as an exhibit hereto and incorporated by reference herein. | ||||